Premium
Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors
Author(s) -
PerezSomarriba Marta,
MorenoTejero Maria Luisa,
Rozas Maria Isabel,
Pelaez Irene,
Madero Luis,
Lassaletta Alvaro
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28089
Subject(s) - medicine , oxaliplatin , gemcitabine , germ cell tumors , paclitaxel , refractory (planetary science) , oncology , chemotherapy , germinoma , germ cell , cancer , biochemistry , chemistry , physics , colorectal cancer , astrobiology , gene
Abstract Intracranial germ cell tumors (GCT) account for less than 5% of all central nervous system tumors in children in Western countries. Approximately 40% are nongerminomatous GCT (NGGCT). Despite correct treatment, 16% to 47% of the patients will relapse. There are no standard approaches in case of recurrence, and treatment in this situation remains a challenge. We report three patients diagnosed with relapsed intracranial NGGCT treated with gemcitabine, paclitaxel, and oxaliplatin, in whom the tumor showed a remarkable response with normalization of tumor markers.